A filing with the US Securities and Exchange Commission (SEC) reveals details of Kyverna Therapeutics’ bid to tap into an increasingly favorable market for init 2 February 2024
Industry observers are cautiously hoping that early 2024 signs indicate that the post-pandemic biotech fundraising slowdown might be coming to and end. 30 January 2024
Stimulants, amphetamines and methylphenidates are the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the sev 18 January 2024
Two new initial public offerings (IPO) are set to go ahead in the USA, raising hopes of a thaw in what has been a long winter for biotech companies going public 17 January 2024
Switzerland-based Stalicla, a biopharma advancing precision medicine pipelines for neuropsychiatric and neurological disorders, has announced the successful com 16 January 2024
Privately-held Spanish drugmaker Ferrer has reported that the Phase III ADORE trial of oral edaravone formulation (FAB122) in amyotrophic lateral sclerosis (ALS 11 January 2024
Belgium’s UCB (Euronext: UCB) has won European Commission (EC) approval for Rystiggo (rozanolixizumab) as an add-on to standard therapy for generalized myasthen 8 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.